Levi & Korsinsky announces it has commenced an investigation of Gilead
Sciences Inc. (“Gilead Sciences” or the “Company”) (NASDAQ:GILD)
concerning possible violations of federal securities laws.
On May 6, 2016, Gilead acknowledged receipt of a subpoena from the U.S.
Attorney’s Office for the District of Massachusetts in February 2016.
According to the Company, the subpoena requested documents related to
the Company’s “support of 501(c)(3) organizations that provide financial
assistance to patients, and for our HCV products, documents concerning
our provision of financial assistance to patients.” Then on May 27,
2016, Bloomberg reported that Gilead is one of three major
drugmakers to disclose in a recent SEC filing the receipt of a subpoena
as part of this expanding federal investigation. To obtain additional
information about the investigation, go to:
or contact Eduard Korsinsky, Esq. either via email at firstname.lastname@example.org
or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New
Jersey, California, Connecticut, and Washington D.C. The firm’s
attorneys have extensive expertise and experience representing investors
in securities litigation involving financial fraud, and have recovered
hundreds of millions of dollars for aggrieved shareholders. Attorney
advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160527005784/en/